SCHEDULE: EcoR1 Capital Reports Zero Stake in Voyager Therapeutics

EcoR1 Capital, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, reporting zero beneficial ownership in Voyager Therapeutics, Inc. common stock.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in Voyager Therapeutics, Inc. common stock.
• The reporting persons collectively declared 0% beneficial ownership of Voyager Therapeutics, Inc. common stock as of the event date of March 31, 2026.
• This filing indicates that EcoR1 Capital, LLC, which previously held a reportable stake, no longer beneficially owns 5% or more of Voyager Therapeutics' common stock.
• Oleg Nodelman is identified as the control person of EcoR1 Capital, LLC, which acts as the general partner and investment adviser for investment funds, including EcoR1 Capital Fund Qualified, L.P.
• The reporting persons certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of Voyager Therapeutics, Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative because a significant institutional investor, EcoR1 Capital, has reported zero beneficial ownership, indicating a complete exit or reduction of their stake below the reporting threshold.

Negatives

• A previously reporting institutional investor, EcoR1 Capital, LLC, has reduced its beneficial ownership in Voyager Therapeutics, Inc. common stock to 0%, indicating a complete divestment or reduction below the 5% reporting threshold.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors to report their beneficial ownership in public companies. An amendment reporting zero ownership typically signifies that the investor has either fully divested their stake or reduced it below the 5% threshold requiring disclosure, which can be a signal to the market regarding institutional sentiment towards the company.

Stakeholder Impact

• Shareholders may interpret the complete divestment by EcoR1 Capital as a negative signal regarding the company's prospects or the investor's reallocation of capital, potentially influencing market sentiment and share price.

Key Dates

Recommendation

While the complete divestment by a previously reporting institutional investor is a notable event, this Schedule 13G filing alone does not provide sufficient fundamental information about Voyager Therapeutics, Inc. to issue a strong buy or sell recommendation. Investors should consider this information in conjunction with the company's financial performance, strategic developments, and broader market conditions.

Keywords

Voyager Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Divestment